San Diego-based mostly Viking Therapeutics marked itself as a significant competitor during the weight loss drug market in February immediately after revealing promising knowledge from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when specified to be a weekly injection As well